TGF-β inhibitors(Transforming growth factor beta inhibitors), αvβ1 inhibitors(Integrin alpha-V/beta-1 inhibitors), αvβ6 antagonists(Integrin alpha-V/beta-6 antagonists)

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

Cholangitis, SclerosingFibrosis, Liver

Inactive Indication

COVID-19Idiopathic Pulmonary FibrosisMediastinal Diseases+ [1]

Originator Organization

Pliant Therapeutics, Inc.

Active Organization

Pliant Therapeutics, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC27H36N6O3

InChIKeyCWOFQJBATWQSHL-DEOSSOPVSA-N

CAS Registry2376257-44-0

Clinical Trials associated with Bexotegrast

NCT06097260

/ TerminatedPhase 2

A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

Start Date16 Nov 2023

Sponsor / Collaborator

Pliant Therapeutics, Inc.

NCT05621252

/ CompletedPhase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.

Start Date13 Jul 2022

Sponsor / Collaborator

Pliant Therapeutics, Inc.

NCT04565249

/ TerminatedPhase 2

A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)

Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19

Start Date22 Oct 2020

Sponsor / Collaborator

Pliant Therapeutics, Inc.

100 Clinical Results associated with Bexotegrast

100 Translational Medicine associated with Bexotegrast

100 Patents (Medical) associated with Bexotegrast

Literatures (Medical) associated with Bexotegrast

01 Jan 2026·JOURNAL OF HEPATOLOGY

Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis

Article

Author: Clark, Annie ; Kowdley, Kris V ; Barnes, Chris N ; Orman, Eric ; Hameed, Bilal ; Pencek, Richard ; Levy, Cynthia ; Bowlus, Christopher L ; Lefebvre, Éric A ; Hirschfield, Gideon M ; Vincent, Catherine ; An, Mahru C ; Thorburn, Douglas ; Trauner, Michael ; Joshi, Deepak ; Eksteen, Bertus ; Chen, Tianyan ; Reddy, K Gautham ; Montano-Loza, Aldo J ; Schaub, Johanna R ; Schramm, Christoph ; Trivedi, Palak J ; Goel, Aparna

BACKGROUND & AIMS:

Transforming growth factor-β signaling activated by α_vβ₆ and α_vβ₁ integrins drives liver fibrosis in primary sclerosing cholangitis (PSC). The aim of this study was to investigate the safety and exploratory pharmacodynamics of bexotegrast (PLN-74809), an oral, once-daily inhibitor of α_vβ₆ and α_vβ₁ integrins, in participants with PSC and liver fibrosis.

METHODS:

In this phase II, double-blind, dose-ranging study, 117 participants with PSC were randomized 3:1 to receive once-daily oral bexotegrast or placebo in three cohorts: 40 mg or placebo for 12 weeks (part 1); 80 mg, 160 mg, or placebo for 12 weeks (part 2); and 320 mg or placebo for up to 40 weeks (part 3). The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs). Exploratory pharmacodynamic endpoints included changes in alkaline phosphatase values, enhanced liver fibrosis (ELF) scores, neoepitope-specific N-terminal pro-peptide of type III collagen (PRO-C3) levels, liver stiffness measurements, gadoxetate-enhanced MRI measures, and the Itch Numeric Rating Scale.

RESULTS:

A total of 117 participants received bexotegrast (40 mg [n = 22], 80 mg [n = 21], 160 mg [n = 21], 320 mg [n = 27]) or placebo (n = 30). Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (72.7% and 70.0%). TEAEs were mild to moderate, and no serious TEAEs related to study drug were observed. Numerically less pharmacodynamic progression was observed with bexotegrast in ELF score, PRO-C3, and MRI assessments at Week 12 compared with placebo. Pharmacodynamic results at Week 24 showed limited change from Week 12 except in MRI parameters which continued to improve.

CONCLUSIONS:

Bexotegrast was well tolerated for up to 40 weeks in participants with PSC and liver fibrosis and was associated with numerically less progression in exploratory pharmacodynamic markers.

IMPACT AND IMPLICATIONS:

Primary sclerosing cholangitis (PSC) is a rare cholestatic disease of unknown etiology. Currently, there is an unmet medical need for safe and effective therapies capable of halting or reversing progression of PSC. In this phase II study in participants with PSC and suspected liver fibrosis, bexotegrast, an oral, once-daily, dual selective inhibitor of α_vβ₆ and α_vβ₁ integrins, had a favorable safety and tolerability profile. This study supports targeting integrin-mediated transforming growth factor-β activation as a potential therapeutic approach for PSC.

TRIAL REGISTRATION NUMBER:

NCT04480840.

01 Jul 2025·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Dual α _v β ₆ and α _v β ₁ Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

Article

Author: Zhou, Iris Y. ; Susnjar, Antonia ; Efthimiou, Nikos ; Catana, Ciprian ; Barnes, Chris N. ; Decaris, Martin ; Fromson, Caroline ; Montesi, Sydney B. ; Clark, Annie ; Turner, Scott M. ; Lefebvre, Éric A. ; Cosgrove, Gregory P. ; Caravan, Peter

Rationale: Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of type I collagen. ⁶⁸Ga-CBP8, a type I collagen positron emission tomography probe, measures collagen accumulation and shows higher collagen deposition in patients with IPF. Bexotegrast (PLN-74809) is an oral, once-daily, dual-selective inhibitor of α_vβ₆ and α_vβ₁ integrins under late-stage evaluation for treatment of IPF. Objectives: To evaluate changes in type I collagen in the lungs of participants with IPF after treatment with bexotegrast. Methods: In this phase 2 (NCT05621252), single-center, double-blind, placebo-controlled study, adults with IPF received bexotegrast 160 mg or placebo for 12 weeks. The primary endpoint was the change in whole-lung standardized uptake value of ⁶⁸Ga-CBP8 positron emission tomography. Changes in lung dynamic contrast-enhanced magnetic resonance imaging parameters, FVC, cough severity, and biomarkers of collagen synthesis and progressive disease were also assessed. Measurements and Main Results: Of 10 participants, 7 received bexotegrast and 3 received placebo. At Week 12, the mean change from baseline in the top quartile of ⁶⁸Ga-CBP8 whole-lung standardized uptake value was -1.2% with bexotegrast versus 6.6% with placebo; the greatest mean changes were observed in subpleural lung regions in both groups (bexotegrast, -3.7%; placebo, 10.3%). Dynamic contrast-enhanced magnetic resonance imaging showed numerically increased peak enhancement and faster contrast washout rate in bexotegrast-treated participants, suggesting improvements in lung microvasculature and decreased extravascular extracellular volume. Bexotegrast treatment resulted in numerical improvements in FVC, cough severity, and biomarkers. Conclusions: The reduced uptake of ⁶⁸Ga-CBP8 in the lungs of participants with IPF indicates an antifibrotic effect of bexotegrast, suggesting the potential for favorable lung remodeling. Clinical trial registered with www.clinicaltrials.gov (NCT05621252).

25 Apr 2025·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

GOAT: A Global Optimization Algorithm for Molecules and Atomic Clusters

Article

Author: de Souza, Bernardo

Abstract:

In this work, we propose a new Global Optimization Algorithm (GOAT) for molecules and clusters of atoms and show how it can find the global energy minima for both systems without resorting to molecular dynamics (MD). This avoids the potential millions of time‐consuming gradient calculations required by a long MD run. Because of that, it can be used with any regular quantum chemical method, even with the costlier hybrid DFT. We showcase its accuracy by running it on various systems, from organic molecules to water clusters, metal complexes, and metal nanoparticles, comparing it with state‐of‐the‐art methods such as the Conformer‐Rotamer Ensemble Sampling Tool (CREST). We also discuss its underlying theory and mechanisms for succeeding in challenging cases. GOAT is, in general, more efficient and accurate than previous algorithms in finding global minima and succeeds in cases where others cannot due to the free choice for the Potential Energy Surface (PES).

139

News (Medical) associated with Bexotegrast

20 Mar 2025

·www.globenewswire.com

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses March 17, 2025 -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a 50% objective response rate (ORR) at the highest dose tested to date. PLN-101095 was generally well tolerated across all doses tested. Nine patients with six different tumor types were enrolled in cohorts one through three of the trial. Patients were treated for 14 days with PLN-101095 at doses of 250 mg, 500 mg or 1000 mg administered orally BID, followed by treatment with a combination of PLN-101095 and pembrolizumab at 200 mg administered intravenously every three weeks (Q3W). Scans were conducted at baseline, Day 14, Week 10, and every 8 weeks thereafter. The Company reported the following initial observations from the trial: Across all doses tested, PLN-101095 was generally well tolerated Of the six patients treated at the 1000 mg BID dose of PLN-101095, three (50%) confirmed partial responses were observed. All three patients remain on treatment. Non-Small Cell Lung Cancer (NSCLC): Confirmed partial response with a 74% reduction in tumor size at Week 18; initial partial response was observed at Week 10 Cholangiocarcinoma: Confirmed partial response with a 48% reduction in tumor size at Week 42; initial partial response was observed at Week 34 Melanoma: Confirmed partial response with a 42% reduction in tumor size at Week 27; initial partial response was observed at Week 18 “We are encouraged by these early responses given the refractory nature of the patient population enrolled in this trial,” said Éric Lefebvre, M.D., Chief Medical Officer of Pliant. “We look forward to sharing the final results from this trial in the future.” The Phase 1 trial of PLN-101095 is currently enrolling the fourth of five potential cohorts. The fourth cohort is evaluating PLN-101095 at 1000 mg, three times daily (TID). PLN-101095 is an oral small molecule inhibitor of integrins αvβ8 and αvβ1. It is currently being evaluated in an ongoing first-in human Phase 1 dose-escalation trial. The open-label trial (NCT06270706) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of PLN-101095 alone and in combination with the immunotherapy pembrolizumab. Activated transforming growth factor-β (TGF-β) has shown to foster an immuno-suppressive tumor microenvironment (TME) that contributes to immune-checkpoint inhibitor (ICI) resistance and treatment failure in cancer.1 Blocking integrins αvβ8 and αvβ1 has shown to prevent the activation of TGF-β and is expected stimulate immune activation by increasing immune cell infiltration into the tumor microenvironment.2,3 In preclinical studies, PLN-101095 demonstrated monotherapy activity in reduction of tumor volume and increased cluster of differentiation (CD)8+ T cell infiltration. In addition, PLN-101095 in combination with an anti-PD-1 monoclonal antibody (mAb) elicited a dose-dependent reduction in tumor volume and increased CD8+ T cell tumor infiltration in the tumor microenvironment compared with anti-PD-1 mAb therapy alone.4 Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvβ8and αvβ1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvβ8 and αvβ1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies. 1 Pickup M. et al. Nat Rev Cancer. 2013 Nov;13(11):788-99. 2 Takasaka N. et al. JCI Insight. 2018 Oct 18;3(20). 3 Reed NI. et al. Sci Transl Med. 2015 May 20;7(288):288ra79. 4 Kothari V, et al. J Immunother Cancer 2022;10(Suppl 2): A1403 abstract 1352 (SITC 2022) The content above comes from the network. if any infringement, please contact us to modify.

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Orphan DrugFast TrackClinical ResultImmunotherapy

14 Mar 2025

·www.fiercebiotech.com

Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms

Acelyrin was explicit that it had made the changes in response to the “continued rapid accumulation” of 8.8% of the biotech’s stock by Tang Capital Partners.\n With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition.Both Pliant and Acelyrin have implemented their own “poison pill” plans. The rule changes mean that if a single investor secures 10% or more of either company’s stock, it will trigger certain changes that could make it harder for a buyer to hoover up the remaining shares.Acelyrin was explicit that it had made the changes in response to the “continued rapid accumulation” of 8.8% of the biotech’s stock by Tang Capital Partners. Acelyrin had already turned down a proposal earlier this month to be bought out by Tang-owned Concentra Biosciences, which came in the middle of plans for Acelyrin to merge with immune-mediated disease specialist Alumis. Pliant didn’t namecheck Concentra when erecting its own stock defence, only stating that it is “intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the board sufficient opportunity to make informed judgments and take actions that are in the best interests of all stockholders.”However, a Securities and Exchange Commission filing shows that earlier this month Tang and its various entities together accrued 9.6% of Pliant’s stock.Tang has a track record of swooping in to try to acquire struggling biotechs—with mixed results. The company bought Jounce Therapeutics and Theseus Pharmaceuticals in 2023 but had its advances rejected by Atea Pharmaceuticals, Rain Oncology, LianBio and Kezar Life Sciences.In one instance back in 2023, Quince Therapeutics resorted to a similar poison pill strategy to ward off potential buyers, one of which was Concentra.Pliant seems to fit the bill for a potential Concentra target, with the biotech’s idiopathic pulmonary fibrosis treatment bexotegrast struggling with increased adverse events in a phase 2b/3 trial this year.

Acquisition

14 Mar 2025

·www.biospace.com

Pliant Pops Poison Pill as Concentra Threat Looms

iStock, Lightspruch Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect shareholders against Tang Capital’s growing stake in the company. Pliant Therapeutics on Thursday launched a limited-duration stockholder rights program—commonly known as a “poison pill defense”—just days after Kevin Tang’s Concentra Biosciences snapped up a sizeable stake in the California-based biotech. Under the defense strategy, shareholders will be able to purchase additional shares of Pliant’s common stock at a 50% discount. The poison pill also assures stockholders that if a so-called “unapproved” company purchases at least 10% of Pliant’s stock and then acquires or merges with the biotech, shareholders would be entitled to buy shares of this theoretical, new third-party company at a 50% discount. The stockholder rights program is set to expire on March 11, 2026, at the latest, as per Thursday’s news release. In adopting the poison pill, Pliant follows in the footsteps of Acelyrin, which on Thursday also initiated a stockholder rights plan, explicitly to protect its stockholders from the “continued and rapid accumulation” of the biotech’s shares by Tang Capital Partners. The investment firm has, in recent weeks, been growing its stake in Acelyrin, reaching 8.8% shares on Monday. In Pliant’s case, while the biotech did not refer to any specific “unapproved” company, it enacted the poison pill defense just days after Tang Capital carved out a 9.6% stake in the company—just shy of the 10% threshold set in the stockholder rights program. Kevin Tang, who owns Tang Capital, is known for this aggressive type of maneuver, often with sights set on a struggling biotech. In December 2023, for instance, Tang’s Concentra Biosciences filed an unsolicited proposal to acquire LianBio, which just days later rejected the offer, saying that it undervalued the biotech. LianBio ultimately shut down last month. Pliant has similarly run into a rough patch, with the biotech last month being forced to suspend its Phase IIb/III BEACON-IPF study, which was testing the integrin blocker bexotegrast for idiopathic pulmonary fibrosis. Pliant at the time did not reveal the exact reason for the pause, though it did assemble a panel of external and independent experts to review the study’s data to determine the best development path forward for bexotegrast. Earlier this month, Pliant announced that it would discontinue BEACON-IPF after a data review found an imbalance in adverse events in patients treated with the candidate. Compounding Pliant’s woes is Novartis’ decision last month to turn its back on the companies’ metabolic dysfunction-associated steatohepatitis candidate PLN-1474. Pliant and Novartis first linked up in 2019 , and despite losing a powerhouse partner, Pliant continues to assess its options for PLN-1474, including another partnership.

Acquisition

100 Deals associated with Bexotegrast

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 3	United States	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Japan	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Argentina	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Australia	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Belgium	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Brazil	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Canada	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Chile	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Czechia	Pliant Therapeutics, Inc.	27 Sep 2023
Idiopathic Pulmonary Fibrosis	Phase 3	Denmark	Pliant Therapeutics, Inc.	27 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04480840 (INTEGRIS-PSC \| INTEGRIS-PSC , CTgov)	Phase 2	Fibrosis, Liver \| Cholangitis, Sclerosing	121	Placebo (Placebo)	zzxvulmkdd = ywegnddgqd qzidvpjygq (hwlfnhzanv, ognctpqddb - psknberanh) View more	-	23 Jan 2026
				PLN-74809 (PLN-74809 Dose Level 1)	zzxvulmkdd = wtieqtzoiz qzidvpjygq (hwlfnhzanv, yrdhwxwzjr - lfzyuuayfv) View more
NCT05621252 (PLN-74809, CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	10	PLN-74809 (PLN-74809)	cnzdoakfuf(wuuiuujmuw) = ixivluvzxv okemswlued (ieanwqbeud, 0.10145) View more	-	24 Sep 2025
				Placebo (Placebo)	cnzdoakfuf(wuuiuujmuw) = zojphhiayg okemswlued (ieanwqbeud, 0.11839) View more
NCT04480840 (INTEGRIS-PSC, GlobeNewswire) Manual	Phase 2	Cholangitis, Sclerosing	36	Bexotegrast	cgkmfckijn(poropmjixu) = None twxuvsfyte (rqnlrmpbdt ) View more	Positive	15 Jul 2024
				Placebo
NCT04396756 (INTEGRIS-IPF, ATS2024) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	88	Bexotegrast (40 mg)	kyvizbuukf(tfgzivixos) = vryrsbrkjm uiggwdeynt (xtitivfysy, 4.80) View more	Positive	21 May 2024
				Bexotegrast (80 mg)	kyvizbuukf(tfgzivixos) = cvhpdzddqs uiggwdeynt (xtitivfysy, 4.19) View more
ATS2024	Not Applicable	Idiopathic Pulmonary Fibrosis \| Cholangitis, Sclerosing	-	Bexotegrast	vvpcfkdiau(esxuivndoc) = The most common system organ class AEs were gastrointestinal-related, including diarrhea, nausea and constipation nserxzxysf (grfrdaxurh ) View more	-	19 May 2024
				Placebo
NCT04396756 (INTEGRIS-IPF, CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	120	Placebo	pkeeblhakk(giztgjpnhz) = szyiqrpnag xkkfojksqa (beeqjqgrps, omltpytlmx - rpqbfbzrxd) View more	-	30 Apr 2024
NCT04480840 (INTEGRIS-PSC, Corporate Publications) Manual	Phase 2	Fibrosis, Liver \| Cholangitis, Sclerosing	121	PLN-74809 40 mg	pyksytzhqt(rrbpejymbp) = qfonmetxoe psxqgnqloz (pnjottawkj )	Positive	04 Feb 2024
				PLN-74809 80 mg	pyksytzhqt(rrbpejymbp) = rotfjxvemf psxqgnqloz (pnjottawkj )
NCT04072315 (IPF-201, CTgov)	Phase 2	Idiopathic Pulmonary Fibrosis	9	PLN-74809 (60 mg)	cncdpprcsp = qtlsrgrzos azbfacxslu (slhzckxjkv, hxgrvonkgh - fyapwguzqv) View more	-	12 Dec 2023
				PLN-74809 (120 mg and 240 mg)	cncdpprcsp = llhnmllsni azbfacxslu (slhzckxjkv, ojispjxhhz - nwsnzpgbkl) View more
NCT04480840 (INTEGRIS-PSC , Corporate Publications) Manual	Phase 2	Fibrosis, Liver \| Cholangitis, Sclerosing	85	bexotegrast 40 mgbexotegrast 40 mg	jtxodacaje(xwqmmaztjd) = lnaceihdwx pcmlxqqami (gxwcmbryhk )	Positive	26 Sep 2023
				bexotegrastbexotegrast 80 mg	jtxodacaje(xwqmmaztjd) = gdeacvxpqs pcmlxqqami (gxwcmbryhk )
NCT04396756 (INTEGRIS-IPF, ATS2023)	Phase 2	Idiopathic Pulmonary Fibrosis	-	PLN-74809 40 mg	vnbjoxkuha(wkcjpzlexh) = The most common TEAE (incidence of ≥10%) was diarrhea, occurring in 17.9% (12/67; PLN-74809) and 4.3% (1/23; placebo) of participants; all but one event were mild or moderate and all events occurred in participants on approved IPF therapies (nintedanib, n=12; pirfenidone, n=1) dbfhnhmqfp (vguldpxesy ) View more	Positive	21 May 2023
				PLN-74809 80 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bexotegrast

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation